SEC Comment Letter for Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Dec 29, 2017
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: Dec. 29, 2017 · CIK: 0001607678 · Accession: 0000000000-17-045355
AI Filing Summary & Sentiment
Letter
December 28, 2017 Brian Lian, Ph.D. President and Chief Executive Officer Viking Therapeutics, Inc. 12340 El Camino Real, Suite 250 San Diego, CA 92130 Viking Therapeutics, Inc. Registration Statement on Form S-1 Filed December 20, 2017 File No. 333-222202Re: Dear Dr. Lian: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jeff Hartlin
Show Raw Text
December 28, 2017
Brian Lian, Ph.D.
President and Chief Executive Officer
Viking Therapeutics, Inc.
12340 El Camino Real, Suite 250
San Diego, CA 92130
Viking Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 20, 2017
File No. 333-222202Re:
Dear Dr. Lian:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jeff Hartlin